Literature DB >> 22029815

Widening the path to personalized medicine.

Scott A Waldman, Andre Terzic.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 22029815      PMCID: PMC5439890          DOI: 10.1111/j.1752-8062.2011.00345.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


× No keyword cloud information.
  21 in total

1.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Authors:  Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  The roadmap to personalized medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

3.  Molecular diagnostics. At the nexus of individualized medicine, health care delivery, and public policy.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

4.  Translational medicine: path to personalized and public health.

Authors:  Andre Terzic; Scott A Waldman
Journal:  Biomark Med       Date:  2010-12       Impact factor: 2.851

5.  Pharmacoeconomics in the era of individualized medicine.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2008-08       Impact factor: 6.875

Review 6.  Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.

Authors:  I Bernard Weinstein; Andrew K Joe
Journal:  Nat Clin Pract Oncol       Date:  2006-08

Review 7.  Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review.

Authors:  Ronald A Booth; Mohammed T Ansari; Evelin Loit; Andrea C Tricco; Laura Weeks; Steve Doucette; Becky Skidmore; Margaret Sears; Richmond Sy; Jacob Karsh
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

8.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

9.  Molecular therapy drives patient-centric health care paradigms.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2010-08       Impact factor: 4.689

10.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

View more
  1 in total

1.  Personalized medicine for asthma: Are we there yet?

Authors:  Audrey H Poon; Qutayba Hamid
Journal:  Ann Thorac Med       Date:  2012-04       Impact factor: 2.219

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.